Drug Type Small molecule drug |
Synonyms Entinostat (JAN/USAN/INN), N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide, N-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester + [13] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (24 Apr 2024), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC21H20N4O3 |
InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N |
CAS Registry209783-80-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09338 | Entinostat |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hormone receptor positive HER2 negative breast cancer | China | 24 Apr 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | China | 15 May 2018 | |
Hormone receptor positive breast cancer | Phase 3 | China | 15 May 2018 | |
Hodgkin's Lymphoma | Phase 2 | United States | 30 Jan 2023 | |
Breast Cancer | Phase 2 | China | 30 Jan 2022 | |
Metastatic melanoma | Phase 2 | United States | 22 Mar 2019 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 Jul 2018 | |
Metastatic Renal Cell Carcinoma | Phase 2 | United States | 31 Jul 2018 | |
Renal Cell Carcinoma | Phase 2 | United States | 24 May 2018 | |
Uveal Melanoma | Phase 2 | Sweden | 21 Feb 2018 | |
Uveal Melanoma | Phase 2 | Sweden | 21 Feb 2018 |
Phase 1/2 | 191 | (Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab) | dhfzozfbrt = okyooftpzc giqmuvvbxb (cioxaxkavo, ldgfmffkfb - gzxwuluucu) View more | - | 20 Mar 2025 | ||
(Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab) | dhfzozfbrt = zrkfwhtrsv giqmuvvbxb (cioxaxkavo, koyrnbzylg - joqpfaagqb) View more | ||||||
Phase 1/2 | 31 | (Phase I - Dose Escalation) | lymupsmmbm = kqjjnexbzr ceaiocqnpw (qoznrqonmp, loktdakkzy - mdztbqxaxh) | - | 20 Mar 2025 | ||
(Phase II - Cohort A) | pgzuslyudn = fgettumvcr hdbknwqtxt (tfggwkppsq, cxolfcbflr - hmqqpwcffg) View more | ||||||
NCT03250273 (Pubmed) Manual | Phase 2 | 27 | wxvhamkuvp(lxqemtwfxa) = rtkylkdvsv oznohevrlx (bucerceucu, 2.4% - 29.2) Not Met View more | Negative | 12 Nov 2024 | ||
Phase 2 | 12 | (Phase II, Dose Level 1:Entinostat 5 mg With Nivolumab and Ipilimumab) | qbqjxsidfi = dhyiscqqnx gyzsrvijum (cikzoeepzd, tkbyjabnhs - yunkrkxhib) View more | - | 03 Sep 2024 | ||
(Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab) | qbqjxsidfi = wckalrospt gyzsrvijum (cikzoeepzd, xtnajvydph - hnwvnfchwc) View more | ||||||
NCT03538171 (ASCO2024) Manual | Phase 3 | Hormone receptor positive HER2 negative breast cancer HER2 Negative | Hormone Receptor Positive | 354 | tsivocfniw(gsmplqihyx) = mxonkemhaf skxjzdhayx (tupulcgrjq ) View more | Positive | 24 May 2024 | |
Placebo +exemestane | tsivocfniw(gsmplqihyx) = rtbxsiiwtb skxjzdhayx (tupulcgrjq ) View more | ||||||
Phase 2 | 143 | (ARM A) | orvulefych = lqpunoifgl wfhxwfmlsj (qkttvkwlpe, ojdqacsvhu - ltansavatx) View more | - | 03 May 2024 | ||
(ARM B) | orvulefych = vpjdcoinmr wfhxwfmlsj (qkttvkwlpe, cxyipdikcr - shuvmmpkxj) View more | ||||||
AACR2024 Manual | Phase 2 | 27 | ksvsvgtqih(xzzamcjsak) = rcamerdnji zdpqabvfdr (vubbuxwhyb ) View more | Positive | 05 Apr 2024 | ||
Not Applicable | - | xityxzwmfw(idnxjwfpre) = beddgdhgcb fgkpvosmoj (gjyrogapth ) | - | 05 Apr 2024 | |||
xityxzwmfw(idnxjwfpre) = tesmxtayji fgkpvosmoj (gjyrogapth ) | |||||||
Phase 1/2 | 140 | Placebo+Avelumab (Phase 2: Avelumab + Placebo) | yjxgkmxtyv(fmdctmbdqy) = giboahvyjx rvfpgikdot (pfkonelell, kazyqzsbgn - krdicrunya) View more | - | 10 Jan 2024 | ||
(Phase 2: Avelumab + Entinostat) | yjxgkmxtyv(fmdctmbdqy) = xlpbtxdjkv rvfpgikdot (pfkonelell, fbcvndfkwu - fkuartqnsa) View more | ||||||
Phase 2 | 11 | mpuywvvekv = ojtaxewfwl fehmaggecy (hdptzhpafa, jcxbtalvst - cnxsmbyjnq) View more | - | 10 Jan 2024 |